Tissue Regenix Group (TRX)

Sector:

Financials

Index:

FTSE AIM All-Share

69.00p
   
  • Change Today:
      2.50p
  • 52 Week High: 71.50p
  • 52 Week Low: 49.00p
  • Currency: UK Pounds
  • Shares Issued: 70.57m
  • Volume: 45,553
  • Market Cap: £48.70m
  • RiskGrade: 22

Tissue Regenix launches new operating division for 'DermaPure'

By Josh White

Date: Monday 26 Feb 2018

LONDON (ShareCast) - (ShareCast News) - Regenerative medical devices company Tissue Regenix Group announced the launch of a new operating division on Monday - 'TRX BioSurgery'.
The AIM-traded firm said 'DermaPure', a decellularised, room-temperature stable dermal allograft, would be the flagship product under the TRX BioSurgery division.

Currently commercialised under Tissue Regenix Wound Care, which would begin operating as 'TRX BioSurgery', DermaPure had proven successful in multiple surgical applications.

Due to DermaPure's impressive single application clinical outcomes, the board said it had been adopted by surgeons within the acute surgical, wound reconstruction, and traditional advanced wound care markets.

In particular, DermaPure said it had seen "significant" uptake in the orthopaedic trauma and urogynaecology segments, where treatment innovation was in high demand.

In order to further expand the opportunity, Tissue Regenix said it had entered an exclusive distribution partnership with ARMS Medical - a specialist distributor in the urogynaecology segment.

The multi-year agreement would give ARMS Medical exclusive rights to distribute DermaPure to hospitals and surgeons throughout the United States for use in urology and gynecology procedures.

Tissue Regenix said the partnership would allow its direct sales force to maintain their focus on soft tissue regeneration in the wound, plastics, orthopaedics and general surgery markets.

"We are excited to announce the launch of the BioSurgery division," said CEO Steve Couldwell.

"Progressing from traditional wound care clinical settings to surgical applications is a natural evolution for DermaPure, which has proven to be clinically efficient in just a single application.

"Our partnership with ARMS Medical, who are known for bringing innovation to women's pelvic health solutions, allows us to leverage their strong relationships with key opinion leaders in the urogynaecology space to further access this market, whilst also maintaining commercial focus in our other key areas."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

TRX Market Data

Currency UK Pounds
Share Price 69.00p
Change Today 2.50p
% Change 3.76 %
52 Week High 71.50p
52 Week Low 49.00p
Volume 45,553
Shares Issued 70.57m
Market Cap £48.70m
RiskGrade 22

TRX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
45.08% below the market average45.08% below the market average45.08% below the market average45.08% below the market average45.08% below the market average
55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average
Price Trend
85.84% above the market average85.84% above the market average85.84% above the market average85.84% above the market average85.84% above the market average
75.86% above the sector average75.86% above the sector average75.86% above the sector average75.86% above the sector average75.86% above the sector average
Income Not Available
Growth
21.89% above the market average21.89% above the market average21.89% above the market average21.89% above the market average21.89% above the market average
17.43% above the sector average17.43% above the sector average17.43% above the sector average17.43% above the sector average17.43% above the sector average

TRX Dividends

No dividends found

Trades for 31-May-2024

Time Volume / Share Price
16:01 2,000 @ 69.82p
15:59 2,280 @ 69.50p
15:32 480 @ 68.00p
15:18 71 @ 69.50p
14:02 400 @ 70.00p

TRX Key Personnel

CEO Daniel Lee
CFO David Cocke

Top of Page